Monitoring and Dosing of Argatroban in a Patient With Antiphospholipid Syndrome.
Hosp Pharm
; 56(6): 706-708, 2021 Dec.
Article
en En
| MEDLINE
| ID: mdl-34732926
ABSTRACT
Background:
This case reports outlines argatroban dosing and necessary dose adjustments in a 56 year-old male with a past medical history of antiphospholipid syndrome and heparin-induced thrombocytopenia.Method:
Argatroban was initiated as a fixed dose of 0.5 µg/kg/min with all initial aPTTs above goal. Argatroban was held for a procedure and re-initiated at 0.25 µg/kg/min. The dose was increased or decreased by 25% from the current rate based on supratherapeutic and subtherapeutic aPTTs, respectively.Results:
The patient remained on argatroban for 6 total days, while achieving goal aPTT levels with no VTE or bleeding events.Conclusion:
Our patient represents the first reported case of monitoring argatroban with aPTTs in an individual with APS.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Idioma:
En
Revista:
Hosp Pharm
Año:
2021
Tipo del documento:
Article
País de afiliación:
Estados Unidos